Bonnici François, Keavney Bernard, Collins Rory, Danesh John
Clinial Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE.
BMJ. 2002 Sep 7;325(7363):517-20. doi: 10.1136/bmj.325.7363.517.
To assess the association between genotype at the insertion or deletion polymorphism of the angiotensin converting enzyme gene and risk of coronary restenosis after percutaneous coronary intervention.
Meta-analysis of studies before July 2001 that reported on these genotypes and risk of coronary restenosis after a percutaneous coronary intervention, with or without coronary stenting.
16 studies, involving 4631 patients undergoing a percutaneous coronary intervention, yielded 1683 patients with restenosis after a mean weighted follow up of 5.5 months. The combined odds ratio for restenosis in people with the DD genotype was 1.23 (99% confidence interval 1.03 to 1.46). When studies were grouped by size, however, the combined odds ratios for restenosis in people with the DD genotype were 1.94 (1.39 to 2.71) for studies with less than 100 cases, 1.33 (0.92 to 1.93) for studies with 100-200 cases, and 0.92 (0.72 to 1.18) for studies with more than 200 cases (trend P=0.02). Similarly, when studies were grouped by genotyping procedures, significantly larger odds ratios were found in the studies that did not conceal disease status from laboratory staff and in the studies that did not use a second polymerase chain reaction amplification to reduce genetic mistyping.
Compared with other studies, larger and more rigorous studies show a weaker association between the angiotensin converting enzyme gene DD genotype and restenosis. Publication bias or detection biases can produce artefactual associations at least as large as those that might be expected for common polymorphisms in complex diseases, suggesting the need for larger and more rigorous genetic epidemiological investigations than are now customary.
评估血管紧张素转换酶基因插入或缺失多态性的基因型与经皮冠状动脉介入治疗后冠状动脉再狭窄风险之间的关联。
对2001年7月之前报告这些基因型以及经皮冠状动脉介入治疗(无论是否使用冠状动脉支架)后冠状动脉再狭窄风险的研究进行荟萃分析。
16项研究涉及4631例接受经皮冠状动脉介入治疗的患者,在平均加权随访5.5个月后,有1683例患者出现再狭窄。DD基因型患者再狭窄的合并比值比为1.23(99%置信区间1.03至1.46)。然而,按研究规模分组时,病例数少于100例的研究中,DD基因型患者再狭窄的合并比值比为1.94(1.39至2.71);病例数为100 - 200例的研究中,该比值比为1.33(0.92至1.93);病例数多于200例的研究中,该比值比为0.92(0.72至1.18)(趋势P = 0.02)。同样,按基因分型程序分组时,在未向实验室工作人员隐瞒疾病状态的研究以及未使用二次聚合酶链反应扩增以减少基因分型错误的研究中,发现的比值比明显更大。
与其他研究相比,规模更大、更严谨的研究显示血管紧张素转换酶基因DD基因型与再狭窄之间的关联较弱。发表偏倚或检测偏倚可能产生的人为关联至少与复杂疾病中常见多态性预期的关联一样大,这表明需要比目前常规的更大、更严谨的遗传流行病学调查。